Skip to main content
Premium Trial:

Request an Annual Quote

Applied Biosystems, Anaspec

Applied Biosystems and its joint venture partner, MDS Analystical Technologies, this week said they plan to commercialize the FlashQuant mass spectrometry platform for drug compound screening. MDS Analytical Technologies was formed when MDS acquired Molecular Devices in March then combined it with MDS Sciex.
FlashQuant is expected to be the first commercially available system combining triple-quadrupole MS with MALDI technology, the companies said in a statement. In tests with the platform, it delivered a 25-fold increase in speed for small-molecule quantitation, compared to the fastest liquid chromatography-coupled triple-quadrupole mass specs currently on the market, the companies said.

Anaspec last week launched 69 new antibodies. They include Anti-Wilm's Tumor Protein, Melanoma, and Anti-Renal Cell Carcinoma.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.